Current status and future of immunotherapy in non-small cell lung cancer

Abstract

Around 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Recent treatment used for NSCLC has been changed to immunotherapy, especially immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and CTLA-4 inhibitors. These treatments increase the overall survival (OS) and progression-free survival (PFS) of patients.